Revenue: $2.8 billion in sales, representing 3% comparable currency neutral growth. Adjusted Operating EBITDA: $578 million, a 9% increase on a comparable currency neutral basis. Adjusted Operating EBITDA Margin: Increased more than 120 basis points to 20.3%. Pharma Solutions Sales: $266 million, an 8% year-over-year increase on a comparable currency neutral basis. Pharma Solutions Adjusted Operating EBITDA: $54 million, a 19% increase versus last year. Taste Sales: $627 million, a 7% year-over-year increase on a comparable currency neutral basis. Taste Adjusted Operating EBITDA Growth: 22% on a comparable currency neutral basis. Food Ingredients Sales: $796 million, a 4% comparable currency neutral decrease from the prior year. Food Ingredients Adjusted Operating EBITDA Growth: 5% on a comparable basis. Health and Bioscience Sales: 5% increase in comparable currency neutral sales. Health and Bioscience Adjusted Operating EBITDA: $138 million, a 3% increase on a year-over-year comparable currency neutral basis. Scent Sales: $614 million, up 4% year over year on a comparable currency neutral basis. Scent Adjusted Operating EBITDA: $144 million, up 4% on a comparable currency neutral basis. Cash Flow from Operations: $127 million year-to-date. Capital Expenditures (CapEx): $179 million, roughly 6% of sales. Dividends Paid: $102 million in the quarter. Gross Debt: Approximately $9.3 billion, a decrease of more than $1 billion compared to the year-ago period. Net Debt to Credit Adjusted EBITDA: 3.9 times. Full-Year 2025 Sales Guidance: $10.6 billion to $10.9 billion, representing currency neutral growth of 1% to 4%. Full-Year 2025 Adjusted Operating EBITDA Guidance: $2 billion to $2.15 billion, representing currency neutral growth of 5% to 10%.

Warning! GuruFocus has detected 7 Warning Signs with IFF.

Release Date: May 07, 2025

For the complete transcript of the earnings call, please refer to the full earnings call transcript.

Positive Points

International Flavors & Fragrances Inc (NYSE:IFF) reported a solid start to 2025 with $2.8 billion in sales, representing 3% comparable currency neutral growth. The company achieved a 9% growth in comparable currency neutral adjusted operating EBITDA, with a margin increase of more than 120 basis points to 20.3%. IFF completed the divestiture of Pharma Solutions two months ahead of schedule, strengthening its capital structure and achieving a net debt to credit adjusted EBITDA ratio of below 3 times. The Taste segment recorded a 7% year-over-year increase in sales, driven by broad-based volume growth across all regions and strong profitability with a 22% growth in adjusted operating EBITDA. IFF's strategic focus on innovation and operational discipline has led to strong performances across multiple segments, including Taste, Pharma Solutions, Scent, and Health and Biosciences.

Story Continues

Negative Points

Volume decline in the Food Ingredients segment was primarily driven by weaker performance in protein solutions and limitations in capacity. The company faced challenges from the broader macroeconomic environment, including potential impacts from global tariffs and trade policy changes. IFF's Food Ingredients segment experienced a 4% decrease in sales on a comparable currency neutral basis, primarily due to sales pressures in protein solutions. The company is concerned about potential economic slowdowns, particularly in the United States, which could impact future performance. IFF's exposure to tariffs, particularly related to China, presents a significant cost challenge, with an estimated $100 million exposure for 2025.

Q & A Highlights

Q: Can you discuss which areas of IFF's portfolio could be at risk and which parts could be more resilient in a recessionary scenario? Are there any signs of a sequential slowdown or caution from your customers? A: Our order book has remained consistent with our guidance. Historically, about 80% of our portfolio is in essential products, making it resilient, while 20% is in discretionary areas like fine fragrances and consumer fragrances. So far, order patterns are solid, but we remain cautious about potential economic uncertainties.

Q: Could you expand on your comments regarding tariffs and their impact on costs? How much of this impact can you mitigate? A: We have about $100 million exposure to tariffs for 2025, primarily related to China. Our global operations allow us to mitigate some impacts through supply chain optimization. For unavoidable costs, we are working with customers on pricing surcharges to fully compensate and target full mitigation over time.

Q: What were the year-ago figures for Flavors and Food Ingredients, and how do they compare on a two-year growth basis? A: Taste grew 11% last year and 7% this year, resulting in a 9% two-year growth rate. Food Ingredients declined 4% last year and this year, but this is largely due to strategic price reductions. On a volume basis, the two-year performance is stronger.

Q: Can you elaborate on the strategic rationale and structure of the EUR130 million joint venture with Kemira called AlphaBio? A: AlphaBio is a 50/50 JV focused on scaling our design enzymatic bio materials technology. We are building a EUR130 million plant in Finland, expected to start by the end of 2027. This JV will serve Kemira's water treatment and packaging markets, while IFF will explore other industrial applications.

Q: With the Pharma sale complete, what's your philosophy on further delevering versus redeploying capital for growth? A: Our focus is on completing our debt tender to achieve a leverage ratio below 3 times net debt to EBITDA. Our priority is reinvesting in CapEx to support core businesses, exploring small bolt-on acquisitions, and evaluating capital returns to shareholders through dividends and potential share buybacks.

For the complete transcript of the earnings call, please refer to the full earnings call transcript.

This article first appeared on GuruFocus.

View Comments